Market Access
Industry exercises option for midpoint review of VPAG Invest...
Under the VPAG agreement, £400 million is available under the VPAG Investment Fund. But what benefits will stay once funding goes away in 2029?
News
Lilly wins new FDA approval for eczema drug Ebglyss
Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.
News
Bayer's asundexian starts EU review for ischaemic stroke
The EMA has started its review of Bayer's asundexian for secondary stroke prevention, keeping it ahead of a rival drug from BMS and J&J.
News
AbbVie's migraine drug cleared for migraine attacks on NHS
AbbVie's Aquipta can now be commissioned by the NHS in England and Wales as an acute treatment for migraine, after a NICE decision.
News
Jen Norton appointed market access leader at EVERSANA
EVERSANA has named Jen Norton as president of its recently formed Market Access & Value division.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
